Olanzapine monotherapy for acute depression in patients with bipolar I or II disorder: Results of an 8-week open label trial

William V Bobo, Richard A. Epstein, Richard C. Shelton

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

We evaluated the efficacy, tolerability, and safety of olanzapine monotherapy in 20 adult patients with bipolar I or II disorder, depressed phase. Patients received open-label olanzapine monotherapy (mean modal dose, 15 mg/day) for 8 weeks. Assessments of psychopathology (Montgomery-Asberg Depression Rating Scale [MADRS], Quick Inventory of Depressive Symptomatology [QIDS-SR-16], Young Mania Rating Scale [YMRS]), clinical global state (Clinical Global Impressions [CGI] scale), and safety/tolerability were performed at baseline, and at 1, 2, 4, 6, and 8 weeks. Seventeen patients (85.0%) completed the study. Improvement in MADRS total scores was observed after the first week of treatment, and at all remaining follow-up time points ( p≤0.005). Parallel improvement in QIDS-SR-16 (p<0.001) and CGI-Severity (p<0.001) was observed between baseline and study endpoint. Nine (45%) subjects achieved positive treatment response, eight of whom (40%) also achieved symptom remission. There were significant increases in weight (+3.2 kg, p=0.001) and body mass index (+1.1 kg/m2, p=0.001), but not fasting glucose or lipids, with the exception of reduced triglyceride levels in the overall sample, and reduced HDL cholesterol in females. Olanzapine may be an effective, well-tolerated option for treating acute non-psychotic depression across a variety of bipolar disorder subtypes.

Original languageEnglish (US)
Pages (from-to)30-36
Number of pages7
JournalHuman Psychopharmacology
Volume25
Issue number1
DOIs
StatePublished - 2010
Externally publishedYes

Fingerprint

olanzapine
Depression
Bipolar Disorder
Safety
Psychopathology
HDL Cholesterol
Fasting
Triglycerides
Body Mass Index
Lipids
Weights and Measures
Glucose
Equipment and Supplies
Therapeutics

Keywords

  • Bipolar i disorder
  • Bipolar ii disorder
  • Depression
  • Efficacy
  • Olanzapine
  • Tolerability

ASJC Scopus subject areas

  • Clinical Neurology
  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Neurology

Cite this

Olanzapine monotherapy for acute depression in patients with bipolar I or II disorder : Results of an 8-week open label trial. / Bobo, William V; Epstein, Richard A.; Shelton, Richard C.

In: Human Psychopharmacology, Vol. 25, No. 1, 2010, p. 30-36.

Research output: Contribution to journalArticle

@article{386fb2e3b9b04dffb68f4d2dde091be3,
title = "Olanzapine monotherapy for acute depression in patients with bipolar I or II disorder: Results of an 8-week open label trial",
abstract = "We evaluated the efficacy, tolerability, and safety of olanzapine monotherapy in 20 adult patients with bipolar I or II disorder, depressed phase. Patients received open-label olanzapine monotherapy (mean modal dose, 15 mg/day) for 8 weeks. Assessments of psychopathology (Montgomery-Asberg Depression Rating Scale [MADRS], Quick Inventory of Depressive Symptomatology [QIDS-SR-16], Young Mania Rating Scale [YMRS]), clinical global state (Clinical Global Impressions [CGI] scale), and safety/tolerability were performed at baseline, and at 1, 2, 4, 6, and 8 weeks. Seventeen patients (85.0{\%}) completed the study. Improvement in MADRS total scores was observed after the first week of treatment, and at all remaining follow-up time points ( p≤0.005). Parallel improvement in QIDS-SR-16 (p<0.001) and CGI-Severity (p<0.001) was observed between baseline and study endpoint. Nine (45{\%}) subjects achieved positive treatment response, eight of whom (40{\%}) also achieved symptom remission. There were significant increases in weight (+3.2 kg, p=0.001) and body mass index (+1.1 kg/m2, p=0.001), but not fasting glucose or lipids, with the exception of reduced triglyceride levels in the overall sample, and reduced HDL cholesterol in females. Olanzapine may be an effective, well-tolerated option for treating acute non-psychotic depression across a variety of bipolar disorder subtypes.",
keywords = "Bipolar i disorder, Bipolar ii disorder, Depression, Efficacy, Olanzapine, Tolerability",
author = "Bobo, {William V} and Epstein, {Richard A.} and Shelton, {Richard C.}",
year = "2010",
doi = "10.1002/hup.1082",
language = "English (US)",
volume = "25",
pages = "30--36",
journal = "Human Psychopharmacology",
issn = "0885-6222",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Olanzapine monotherapy for acute depression in patients with bipolar I or II disorder

T2 - Results of an 8-week open label trial

AU - Bobo, William V

AU - Epstein, Richard A.

AU - Shelton, Richard C.

PY - 2010

Y1 - 2010

N2 - We evaluated the efficacy, tolerability, and safety of olanzapine monotherapy in 20 adult patients with bipolar I or II disorder, depressed phase. Patients received open-label olanzapine monotherapy (mean modal dose, 15 mg/day) for 8 weeks. Assessments of psychopathology (Montgomery-Asberg Depression Rating Scale [MADRS], Quick Inventory of Depressive Symptomatology [QIDS-SR-16], Young Mania Rating Scale [YMRS]), clinical global state (Clinical Global Impressions [CGI] scale), and safety/tolerability were performed at baseline, and at 1, 2, 4, 6, and 8 weeks. Seventeen patients (85.0%) completed the study. Improvement in MADRS total scores was observed after the first week of treatment, and at all remaining follow-up time points ( p≤0.005). Parallel improvement in QIDS-SR-16 (p<0.001) and CGI-Severity (p<0.001) was observed between baseline and study endpoint. Nine (45%) subjects achieved positive treatment response, eight of whom (40%) also achieved symptom remission. There were significant increases in weight (+3.2 kg, p=0.001) and body mass index (+1.1 kg/m2, p=0.001), but not fasting glucose or lipids, with the exception of reduced triglyceride levels in the overall sample, and reduced HDL cholesterol in females. Olanzapine may be an effective, well-tolerated option for treating acute non-psychotic depression across a variety of bipolar disorder subtypes.

AB - We evaluated the efficacy, tolerability, and safety of olanzapine monotherapy in 20 adult patients with bipolar I or II disorder, depressed phase. Patients received open-label olanzapine monotherapy (mean modal dose, 15 mg/day) for 8 weeks. Assessments of psychopathology (Montgomery-Asberg Depression Rating Scale [MADRS], Quick Inventory of Depressive Symptomatology [QIDS-SR-16], Young Mania Rating Scale [YMRS]), clinical global state (Clinical Global Impressions [CGI] scale), and safety/tolerability were performed at baseline, and at 1, 2, 4, 6, and 8 weeks. Seventeen patients (85.0%) completed the study. Improvement in MADRS total scores was observed after the first week of treatment, and at all remaining follow-up time points ( p≤0.005). Parallel improvement in QIDS-SR-16 (p<0.001) and CGI-Severity (p<0.001) was observed between baseline and study endpoint. Nine (45%) subjects achieved positive treatment response, eight of whom (40%) also achieved symptom remission. There were significant increases in weight (+3.2 kg, p=0.001) and body mass index (+1.1 kg/m2, p=0.001), but not fasting glucose or lipids, with the exception of reduced triglyceride levels in the overall sample, and reduced HDL cholesterol in females. Olanzapine may be an effective, well-tolerated option for treating acute non-psychotic depression across a variety of bipolar disorder subtypes.

KW - Bipolar i disorder

KW - Bipolar ii disorder

KW - Depression

KW - Efficacy

KW - Olanzapine

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=76149138035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76149138035&partnerID=8YFLogxK

U2 - 10.1002/hup.1082

DO - 10.1002/hup.1082

M3 - Article

C2 - 20029794

AN - SCOPUS:76149138035

VL - 25

SP - 30

EP - 36

JO - Human Psychopharmacology

JF - Human Psychopharmacology

SN - 0885-6222

IS - 1

ER -